<DOC>
	<DOCNO>NCT01637064</DOCNO>
	<brief_summary>By create registry , physicians opportunity understand clinical outcome Myositis patient treat Acthar . Despite availability clinical exam , muscle biopsy , test , surmise may important classification myositis physician diagnose could possibly lead improper treatment due inaccurate diagnosis . There may several type immune inflammatory myositis ( IIM ) fit well typical sub classification myositis .</brief_summary>
	<brief_title>Dermatomyositis Polymyositis Registry</brief_title>
	<detailed_description>Retrospective prospective data collect physician prescribe Acthar myositis patient determine specific characteristic patient base biopsy analysis , laboratory result , clinical exam . Through biopsy analysis , subcategories IIM determine could illustrate IIMs may responsive Acthar therapy .</detailed_description>
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Polymyositis</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>1 . Age 1885 2 . Male Female 3 . Clinical pathologic diagnosis polymyositis dermatomyositis 4 . Capable provide informed consent comply treatment regimen 1 . History scleroderma , osteoporosis , systemic fungal infection , ocular herpes simplex 2 . Recent surgery , history presence peptic ulcer , congestive heart failure , uncontrolled hypertension , sensitivity protein porcine origin 3 . Any comorbid condition would make completion trial unlikely 4 . If female , pregnant breastfeeding ; , childbearing age , unwillingness use appropriate birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Myositis</keyword>
	<keyword>Acthar treatment</keyword>
</DOC>